FDA Expands Mounjaro Approval to Reduce Cardiovascular Risk
FDA expanded Mounjaro’s approved use to reduce cardiovascular risk in certain adults with type 2 diabetes, broadening its role beyond glucose control and weight management.
Cardiovascular Risk